|
Catalogue Number
|
156376 |
|
Applications
|
FACS
IP
WB
|
|
Antigen/Gene or Protein Targets
|
Lipid Phosphate Phosphohydrolase 3
|
|
Synonyms
|
PLPP3, Dri42, PAP2B, VCIP, PPAP2B or phospholipid phosphatase 3
|
|
Reactivity
|
Human and Mouse
|
|
Relevance
|
An antibody against the extracellular domain of LPP3 inhibits cell-cell interactions and angiogenesis in vitro. In addition, LPP3 not only catalyzes the dephosphorylation of the bioactive lipid sphingosine-1-phosphate (S1P) to generate sphingosine but also may regulate embryonic development and angiogenesis via the Wnt pathway. LPP3 also has the ability to potentiate tumor growth by amplifying B-catenin and CYCLIN-D1 activities. Thus, LPP3 is a potential target for inhibiting the growth of glioblastoma, an aggressive type of brain tumor, and other LPP3-expressing tumors. This may serve as a link in the acquisition of proliferative, invasive, and metastatic phenotypes.
|
|
Host
|
Mouse
|
|
Immunogen
|
A modified synthetic peptide (YRCRGDDSKVQEARKSFFc-KLH) corresponding to 179-196 of human LPP3 conjugated to keyhole limpet hemocyanin
|
|
Positive Control
|
IgG1
|
|
Research Area
|
Adhesion, Cancer, Cell Signaling & Signal Transduction, Cell Structure and Motility
|
